Analyst Ratings For Shire PLC (LON:SHP)
Today, Societe Generale lowered its price target on Shire PLC (LON:SHP) to GBX 6,200 per share.
There are 1 hold rating, 16 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Shire PLC (LON:SHP) is Buy (Score: 3.00) with a consensus target price of GBX 6,015.60 per share, a potential .
Some recent analyst ratings include
- 2/28/2017-Deutsche Bank AG Reiterated Rating of Buy.
- 2/28/2017-Royal Bank of Canada Reiterated Rating of Outperform.
- 2/27/2017-BNP Paribas Reiterated Rating of Outperform.
- 2/20/2017-Goldman Sachs Group Inc Reiterated Rating of Conviction-Buy.
- 2/17/2017-Jefferies Group LLC Reiterated Rating of Buy.
About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Recent Trading Activity for Shire PLC (LON:SHP)
Shares of Shire PLC closed the previous trading session at 5,034.00 down -2.00 -0.04% with 1,679,840 shares trading hands.